Off-Label Benralizumab in Severe Non-Necrotizing Eosinophilic Vasculitis following Critical COVID-19 Disease and in DRESS

Irena Pintea; Ioana Adriana Muntean; Carmen Teodora Dobrican; Nicolae Miron; Diana Deleanu

doi:10.3390/jcm11226642

Off-Label Benralizumab in Severe Non-Necrotizing Eosinophilic Vasculitis following Critical COVID-19 Disease and in DRESS

J Clin Med. 2022 Nov 9;11(22):6642. doi: 10.3390/jcm11226642.

Authors

Irena Pintea^{1

2}, Ioana Adriana Muntean^{1

2}, Carmen Teodora Dobrican^{1

2}, Nicolae Miron³, Diana Deleanu^{1

2}

Affiliations

¹ Department of Allergology and Immunology, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania.
² Allergology Department, Professor Doctor Octavian Fodor Regional Institute of Gastroenterology and Hepatology, 400162 Cluj-Napoca, Romania.
³ Department of Clinical Immunology, Sahlgrenska University Hospital, 41346 Gothenburg, Sweden.

Abstract

Benralizumab is a humanized recombinant mAb that binds to the interleukin 5 receptor (IL-5R) expressed on eosinophils and is approved for the treatment of severe eosinophilic asthma. There are a series of severe eosinophilic disorders that may benefit from this treatment, and it could be a life-saving therapy. In this paper, we present two severe patients with eosinophil-induced diseases that had a good resolution after one dose of Benralizumab 30 mg. The first case is a severe non-necrotizing eosinophilic vasculitis following critical COVID-19 disease and the second case is a DRESS (Drug Rash with Eosinophilia and Systemic Symptoms Syndrome) due to allopurinol. Conclusions: The successful administration of Benralizumab in rare or severe eosinophilic disease could be an option for life-saving therapies when conventional treatments fail.

Keywords: Benralizumab; COVID-19; DRESS; eosinophils; vasculitis.

Grants and funding

This research received no external funding.